1. Schade, David S, Shey, Lynda, Eaton, R Philip. . Cholesterol Review: A Metabolically Important Molecule. In Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 26, 1514-1523. doi:10.4158/EP-2020-0347. https://pubmed.ncbi.nlm.nih.gov/33471744/
2. Liao, Jianwei, Yang, Liyun, Zhou, Luping, Cui, Yimin, Ouyang, Dongsheng. 2022. The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial. In Frontiers in pharmacology, 13, 755469. doi:10.3389/fphar.2022.755469. https://pubmed.ncbi.nlm.nih.gov/35359877/
3. Michaeli, Daniel Tobias, Michaeli, Julia Caroline, Albers, Sebastian, Boch, Tobias, Michaeli, Thomas. 2023. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. In American journal of cardiovascular drugs : drugs, devices, and other interventions, 23, 477-495. doi:10.1007/s40256-023-00594-5. https://pubmed.ncbi.nlm.nih.gov/37486464/
4. Huang, Wuqing, Xiao, Jun, Ji, Jianguang, Chen, Liangwan. 2021. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. In eLife, 10, . doi:10.7554/eLife.73873. https://pubmed.ncbi.nlm.nih.gov/34866576/
5. Li, Yulong, Li, Jiawen, Tang, Xiaofang, Yuan, Jinqing, Zhao, Xueyan. 2024. Association of NPC1L1 and HMGCR gene polymorphisms with coronary artery calcification in patients with premature triple-vessel coronary disease. In BMC medical genomics, 17, 22. doi:10.1186/s12920-024-01802-0. https://pubmed.ncbi.nlm.nih.gov/38233830/
智鼠故事 
